The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for ...

Doctors at Chesapeake Regional Healthcare are able to minimize the pain lung cancer patients undergo with a one-and-done ...

“Early detection can reduce lung cancer death rates by 20% — that’s significant,” Dr. Gorbatov says. “In some cases when we ...

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...

Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

During a shortage of the generic platinum chemotherapy drugs cisplatin and carboplatin that began in early 2023, there was no ...

Martin Dietrich, MD, PhD, discusses how the FDA-approved combination therapy is transforming care for resectable early-stage ...

The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR ...